Key result
Multisystem Langerhans-cell histiocytosis without anterior pituitary deficiency was associated with a decreased insulin resistance index GIR compared to matched controls.
Why the study?
Do adult patients with multisystem Langerhans-cell histiocytosis have an increased cardiovascular and metabolic risk profile compared to matched controls?
Observational (n=56)
Do adult patients with multisystem Langerhans-cell histiocytosis have an increased cardiovascular and metabolic risk profile compared to matched controls?
Adult patients with multisystem Langerhans-cell histiocytosis exhibit abnormalities in glucose metabolism, particularly those with active disease, suggesting an increased metabolic risk potentially linked to chronic inflammation.
Answers are grounded in this paper and cite their sources.
Suggests possible metabolic implications in multisystem LCH; leaves open causal links to cardiovascular risk pending prospective studies.
BACKGROUND: Langerhans-cell histiocytosis (LCH) is a rare disease with features of chronic inflammation and it may also induce hypopituitarism, conditions associated with an increased risk of cardiovascular diseases. AIM: Cardiovascular and metabolic risk profile investigation in multisystem LCH patients with and without anterior pituitary deficiency. DESIGN: Prospective, observational study. METHODS: Fourteen adult patients with LCH, 7 with and 7 without anterior pituitary deficiency, and 42 controls matched for age, body mass index (BMI) and smoking. Cardiovascular risk factors were estimated in all subjects: glucose and lipid profile, mathematical indices of insulin resistance (IR), blood pressure, structural arterial and functional endothelial properties (intima-media thickness, brachial artery flow-mediated dilatation). Cardiovascular risk factors were estimated in the three groups studied; the effect of disease activity and/or treatment was also determined in patients with LCH. RESULTS: Ten patients had diabetes insipidus, and 7 anterior pituitary hormone deficiencies: 8 patients had active disease and 11 had received systemic treatment. No difference was observed between the study groups in vascular parameters, in lipid profile or in blood pressure. However, the insulin resistance index GIR was decreased in patients with LCH without anterior pituitary deficiency compared to controls (P = 0.033). Three patients had impaired glucose tolerance and one diabetes mellitus type 2. These patients were older and had active disease; there was no association with hypopituitarism and/or previous treatment. CONCLUSION: Adults patients with LCH have abnormalities of glucose metabolism that tend to occur in patients with active disease, and may be a consequence of the pro-inflammatory state.
No takes yet. Share an insight, caveat, or question.
Alexandraki et al. (2007) conducted an observational in Multisystem Langerhans-cell histiocytosis (n=56). Multisystem Langerhans-cell histiocytosis vs. Matched controls was evaluated on Insulin resistance index GIR (p=0.033). Multisystem Langerhans-cell histiocytosis without anterior pituitary deficiency was associated with a decreased insulin resistance index GIR compared to matched controls.
Synapse has enriched 10 related papers. Consider them for comparative context: